Rapid7 appointed a new CEO in early June 2026, marking a significant leadership shift. The company launched a Cyber Governance, Risk, and Compliance (GRC) early access program in mid-May.

Varonis Systems delivered strong Q1 2026 results with revenue growth of 27% year-over-year and an earnings beat. Recent product integrations highlight the company’s push into AI-driven data security solutions.

Infosys delivered solid FY26 results with $20.2 billion in revenue and strong free cash flow, though FY27 guidance was conservative at 1.5-3.5% constant-currency growth. Recent weeks featured sharp IT sector volatility, including a multi-day rally followed by profit-taking and broader tech selloffs impacting INFY.

Booz Allen Hamilton reported a strong Q4 FY2026 earnings beat on adjusted EPS of $1.78, exceeding consensus estimates by over 30%. Revenue declined modestly due to softness in the Civil segment, while profitability improved through cost controls and margin expansion.

Leidos reported strong Q1 2026 results with revenue growth and an earnings beat, leading to raised full-year guidance. The company secured multiple major U.

Parsons Corporation secured multiple U. S.

Vail Resorts reported fiscal 2026 third-quarter net income of $314.4 million, down from $389.7 million a year earlier. Resort Reported EBITDA totaled $586.4 million versus $647.7 million in the prior-year period.

Revenue reached $290.9 million, exceeding analyst estimates and reflecting 15% higher avocado volumes. Adjusted earnings per share came in at $0.01, missing consensus estimates.

Graham Corporation reported record quarterly revenue of $67.1 million, up 13% year-over-year. Full-year fiscal 2026 revenue reached a record $245.3 million, a 17% increase from the prior year.

The Campbell's Company reported adjusted EPS of $0.50 for Q3 Fiscal 2026, beating analyst estimates. Net sales declined 4% year-over-year to approximately $2.37 billion, slightly missing expectations.

Anbio Biotechnology (NNNN) shares fell approximately 25% in today’s session. The decline follows the company’s recent IPO and elevated trading levels in prior sessions.

Argan, Inc. (AGX) shares fell approximately 11.50% during the trading session on June 8, 2026.

WLTH shares fell 14.57% as of the latest available price of $8.415 compared with the prior session close of $9.85. The decline followed the release of fiscal first-quarter results that missed Wall Street estimates on both earnings and revenue.

Brady Corporation (BRC) shares fell sharply, declining 16.51% from the prior session’s close of $88.63 to a latest price of $74.00. The move reflects profit-taking following strong gains earlier in the year, including a surge after robust fiscal third-quarter results in May.

GHM shares plunged 16.87% intraday as the stock traded near $89.03 versus the prior close of $107.10. Primary catalyst: Market reaction to fourth-quarter and full-year fiscal 2026 results released ahead of the June 8 conference call.

Ciena Corporation (CIEN) shares declined approximately 5.06% in the latest trading session, extending recent weakness. The primary driver was ongoing investor disappointment following the company’s fiscal second-quarter earnings report earlier in the week, despite a solid beat on revenue and earnings.

FCEL shares fell approximately 11.19% during the June 8 trading session. Primary catalyst: Release of second fiscal quarter 2026 financial results. Secondary drivers: Broader pullback across the fuel cell sector and profit-taking after prior volatility.

INTC shares surged approximately 11.64% in premarket trading on June 8, 2026, to around $110.72 from Friday’s closing price of $99.17. The primary catalyst is the announcement of a strategic partnership between Intel and Hitachi to accelerate physical AI capabilities across industries such as robotics and industrial automation.

Cloudflare delivered strong Q1 2026 results with 34% revenue growth and an earnings beat. The company completed the acquisition of VoidZero to enhance its AI-native web tooling capabilities.

TNGX shares surged approximately 47.03% in premarket trading on June 8, 2026, to around $29.73 from Friday’s closing price of $20.22. The primary catalyst is the announcement of positive initial Phase 1/2 clinical trial results for the combination of vopimetostat and daraxonrasib in pancreatic ductal adenocarcinoma, demonstrating a 92% objective response rate.